Navigation Links
Sanguine BioSciences Announces Distribution Partnership with AMS Biotechnology
Date:8/8/2013

VALENCIA, Calif., Aug. 8, 2013 /PRNewswire/ -- Sanguine BioSciences, a biotechnology company enabling personalized medicine research, today announced a distribution partnership with AMS Biotechnology (AMSBIO) to make its products and services available to researchers in Europe.

Sanguine collects and de-identifies biospecimen, medical history and other data from patients diagnosed with severe and chronic diseases for use in biomarker research. Researchers traditionally obtain biospecimen through hospitals, but this process often proves inefficient as the focus for physicians and staff is on diagnosis and treatment, not facilitating research efforts. By connecting directly with patients, Sanguine can meet the needs of researchers and offer timely turnaround of biospecimen and medical data with diverse ranges for age, race, disease state, gender and treatments underway.  The patient engagement tactics used by the company have led to a 95 percent retention rate, which also allow for follow-up draws for longitudinal studies.

"There is no denying that personalized medicine has become a significant area of interest for drug discovery, but there exists a gap between researchers who require biospecimen respective medical data, and patients who want to be a part of research efforts," said Brian Neman, founder and chief executive officer of Sanguine. "We have engaged hundreds of patient subjects, and built a library of specimen and data that can effectively bridge this gap. We look forward to partnering with AMSBIO to make this service accessible to researchers around the world working in different therapeutic areas." 

Added Phillip Pridham-Field of AMSBIO, "Sanguine's patient retention efforts allow researchers to collect the data they need with better turnaround time and with the potential for longitudinal studies. We believe they will be an excellent addition to our current product offerings for researchers in life sciences."

Sanguine is able to meet, review disclosures and collect blood samples in a patient's home with its own phlebotomists in multiple major U.S. cities. Patients are also able to track how their de-identified biospecimen and data are used through the donor web-portal. The company is able to collect and process blood from patients with any disease and has already built large libraries in multiple chronic and severe conditions, including Huntington's disease, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis and others.

In order to maintain appropriate confidentiality, all samples are de-identified immediately upon collection. Sanguine maintains and reviews internal ethical guidelines for the procedures under high scrutiny from an independent review board.

About Sanguine

Sanguine BioSciences is a biotechnology company bridging the gap between patients and researchers developing personalized medicine. The company engages patients in biomedical research by delivering transparency throughout the research process. Sanguine collects and de-identifies patient-derived data in the form of biospecimen, and physician and self-reported information. These data are generated and then made available to researchers involved in drug and biomarker research and discovery with leading academic laboratories and companies, such as Vertex. (http://sanguinebio.com)

About AMS Biotechnology

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology products and services for research and development in the medical, nutrition, cosmetics and energy industries. With a range of molecular detection reagents and a significant Biorepository AMSBIO offers tissues, DNA, RNA, protein and tissue microarray products. Key research areas for AMSBIO include: Oncology, Regenerative Medicine, Environmental Analysis, Cytotoxicity Screening, Glycomics and Stem Cell Biology.

Media Contact:
Ian Stone
Russo Partners
Tel: +1 619-308-6541
ian.stone@russopartnersllc.com


'/>"/>
SOURCE Sanguine BioSciences
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research, Co-Invest in Sanguine BioSciences
2. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research with Seed Round Investment in Sanguine BioSciences
3. Sanguine Appoints Darlene Rosario, Vice President of Regulatory Affairs & Quality at Biothera, Inc., to Clinical Advisory Board and Ethics Committee
4. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
5. Flagship Biosciences Expands Digital Pathology with Pharmaceutical Biostatistics Services
6. Neurocrine Biosciences Reports Second Quarter 2013 Results
7. Centrillion Biosciences Announces Winners of Next-gen Sequencing Innovation Grant Program
8. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
9. Flagship Biosciences Introduces a New Technique for Measuring Fibrosis in Nonalcoholic Steatohepatitis
10. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
11. Eagle Biosciences Introduces Highly Sensitive Calprotectin ELISA Assay Kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. Stock-Callers.com has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
Breaking Biology News(10 mins):